These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The inhibition of interleukin 1-stimulated cartilage proteoglycan degradation by cysteine endopeptidase inactivators. Buttle DJ; Saklatvala J; Barrett AJ Agents Actions Suppl; 1993; 39():161-5. PubMed ID: 8456627 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin 1-stimulated cartilage proteoglycan degradation by a lipophilic inactivator of cysteine endopeptidases. Buttle DJ; Saklatvala J; Tamai M; Barrett AJ Biochem J; 1992 Jan; 281 ( Pt 1)(Pt 1):175-7. PubMed ID: 1731753 [TBL] [Abstract][Full Text] [Related]
4. The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B. Crawford C; Mason RW; Wikstrom P; Shaw E Biochem J; 1988 Aug; 253(3):751-8. PubMed ID: 2845932 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Buttle DJ; Handley CJ; Ilic MZ; Saklatvala J; Murata M; Barrett AJ Arthritis Rheum; 1993 Dec; 36(12):1709-17. PubMed ID: 8250991 [TBL] [Abstract][Full Text] [Related]
6. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Lalmanach G; Mayer R; Serveau C; Scharfstein J; Gauthier F Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):395-9. PubMed ID: 8809025 [TBL] [Abstract][Full Text] [Related]
7. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Barrett AJ; Kembhavi AA; Brown MA; Kirschke H; Knight CG; Tamai M; Hanada K Biochem J; 1982 Jan; 201(1):189-98. PubMed ID: 7044372 [TBL] [Abstract][Full Text] [Related]
9. The use of benzyloxycarbonyl[125I]iodotyrosylalanyldiazomethane as a probe for active cysteine proteinases in human tissues. Mason RW; Bartholomew LT; Hardwick BS Biochem J; 1989 Nov; 263(3):945-9. PubMed ID: 2597135 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and properties of Cbz-Phe-Arg-CHN2 (benzyloxycarbonylphenylalanylarginyldiazomethane) as a proteinase inhibitor. Zumbrunn A; Stone S; Shaw E Biochem J; 1988 Mar; 250(2):621-3. PubMed ID: 3355540 [TBL] [Abstract][Full Text] [Related]
13. Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism. Sztrolovics R; White RJ; Poole AR; Mort JS; Roughley PJ Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):571-7. PubMed ID: 10215595 [TBL] [Abstract][Full Text] [Related]
14. Cathepsin B and L activities in isolated osteoclasts. Rifkin BR; Vernillo AT; Kleckner AP; Auszmann JM; Rosenberg LR; Zimmerman M Biochem Biophys Res Commun; 1991 Aug; 179(1):63-9. PubMed ID: 1883385 [TBL] [Abstract][Full Text] [Related]
15. Cystatin C based peptidyl diazomethanes as cysteine proteinase inhibitors: influence of the peptidyl chain length. Hall A; Abrahamson M; Grubb A; Trojnar J; Kania P; Kasprzykowska R; Kasprzykowski F J Enzyme Inhib; 1992; 6(2):113-23. PubMed ID: 1284427 [TBL] [Abstract][Full Text] [Related]
16. A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia. Seyfried DM; Veyna R; Han Y; Li K; Tang N; Betts RL; Weinsheimer S; Chopp M; Anagli J Brain Res; 2001 May; 901(1-2):94-101. PubMed ID: 11368955 [TBL] [Abstract][Full Text] [Related]
17. The identification of active forms of cysteine proteinases in Kirsten-virus-transformed mouse fibroblasts by use of a specific radiolabelled inhibitor. Mason RW; Wilcox D; Wikstrom P; Shaw EN Biochem J; 1989 Jan; 257(1):125-9. PubMed ID: 2537618 [TBL] [Abstract][Full Text] [Related]
18. A serine proteinase inactivator inhibits chondrocyte-mediated cartilage proteoglycan breakdown occurring in response to proinflammatory cytokines. Bryson H; Bunning RA; Feltell R; Kam CM; Kerrigan J; Powers JC; Buttle DJ Arch Biochem Biophys; 1998 Jul; 355(1):15-25. PubMed ID: 9647662 [TBL] [Abstract][Full Text] [Related]
20. Cysteine cathepsins are not critical for TRAIL- and CD95-induced apoptosis in several human cancer cell lines. Špes A; Sobotic B; Turk V; Turk B Biol Chem; 2012 Dec; 393(12):1417-31. PubMed ID: 23667901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]